Veklury Still Keeping Gilead Above Water Amid Pandemic, Patent Expiries

HIV, Hepatitis Continue To See Sales Declines

 
• By Alaric DeArment

Descovy saw a sales decline, though that was due to payer discounts for PrEP, with the drug’s market share continuing to grow.

Coronavirus globe
Amid the pandemic and other factors, Gilead's Veklury has played a key role in keeping the company's sales afloat • Source: Shutterstock

More from Earnings

More from Business